Pyxis Oncology (PYXS) Profit After Tax (2020 - 2025)
Pyxis Oncology's (PYXS) quarterly Profit After Tax came in at -$18.0 million in Q4 2025, up 49.75% year-on-year from -$12.0 million in Q4 2024, and up 17.89% on a QoQ basis from -$21.9 million in Q3 2025.
Pyxis Oncology (PYXS) Profit After Tax (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Profit After Tax data on file, last reported at -$18.0 million in Q4 2025.
- On a quarterly basis, Profit After Tax rose 49.75% year-over-year to -$18.0 million in Q4 2025; TTM through Dec 2025 was -$79.4 million, a 3.0% decrease from a year earlier, with the FY2025 full-year figure at -$79.6 million, down 3.0% from the prior year.
- Profit After Tax for Q4 2025 stood at -$18.0 million, up from -$21.9 million in the prior quarter.
- Over the last five years, Profit After Tax for PYXS reached as high as -$3.3 million in Q1 2024 and fell as low as -$36.8 million in Q1 2021.
- Historically, Profit After Tax has averaged -$21.4 million across 5 years, with a median of -$20.0 million in 2023.
- Across the five-year window, Profit After Tax jumped 83.08% in 2024 and plunged 549.82% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$16.9 million in 2021, then slumped by 114.1% to -$36.1 million in 2022, then soared by 56.95% to -$15.5 million in 2023, then tumbled by 130.64% to -$35.8 million in 2024, then jumped by 49.75% to -$18.0 million in 2025.
- Per Business Quant data, the three most recent Profit After Tax figures were -$18.0 million in Q4 2025, -$21.9 million in Q3 2025, and -$18.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | -18.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.01 Mn |
| Sep 30, 2025 | -21.93 Mn |
| Jun 30, 2025 | -18.35 Mn |
| Mar 31, 2025 | -21.16 Mn |
| Dec 31, 2024 | -35.83 Mn |
| Sep 30, 2024 | -20.75 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -15.53 Mn |
| Sep 30, 2023 | -23.05 Mn |
| Jun 30, 2023 | -16.68 Mn |
| Mar 31, 2023 | -19.24 Mn |
| Dec 31, 2022 | -36.08 Mn |
| Sep 30, 2022 | -27.67 Mn |
| Jun 30, 2022 | -25.56 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -16.85 Mn |
| Sep 30, 2021 | -14.18 Mn |
| Jun 30, 2021 | -8.15 Mn |
| Mar 31, 2021 | -36.83 Mn |